ClinicalTrials.gg
Status unknownNCT03931577ISAAC-CATUpdated Apr 30, 2019

Effectiveness of Improving Diagnostic and Communication Skills on Antibiotic Prescribing Appropriateness in Acute Cough

An interventional study of C-reactive protein rapid testing and Communication skill enhancement in Respiratory Tract Infections and Cough, sponsored by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina. Status unknown at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-30.

Sponsored by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
2,940
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Despite their marginal benefit, about 60% of uncomplicated acute lower respiratory infections (ALRTI) are currently treated with antibiotics. Several strategies have been developed to reduce inappropriate antibiotic prescribing, with the use of point-of-care C-reactive protein (CRP) testing and the improvement of the communication skills being the most effective interventions, but most of the studies have been carried out outside Mediterranean countries. This study is aimed at evaluating the effect of a disease-focused intervention (CRP) and an illness-focused intervention (improvement of communication skills to optimise doctor-patient consultations and share-decision making with the aid of patient-centred leaflets) on antibiotic prescribing for patients with ALRTIs in Catalan primary care by means of a cluster, randomised, factorial, controlled trial. Primary care centres will be assigned to four trial arms: usual care, use of CRP testing, enhanced communication skills backed up with leaflets, or combined interventions. The main outcome will be antibiotic use within the first 6 weeks and the quality adjusted life years. A pharmacoeconomic analysis of the impact of these interventions will be assessed.

Read the detailed description

Background: Most antibiotics are prescribed in primary care, and most commonly for acute lower respiratory infections (ALRTI). Despite their marginal benefit, about 60% of these infections are currently treated with antibiotics in Catalonia, Spain. Several strategies have been developed to reduce inappropriate antibiotic prescribing, with the use of C-reactive protein (CRP) rapid testing and the improvement of the communication skills being the most effective interventions. However, most studies have been carried out outside Mediterranean countries. This study aims to evaluate the effectiveness and the efficiency of a continuous disease-focused intervention (CRP) and an illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) on antibiotic prescribing in patients with ALRTIs in Catalan primary care centres.

Methods/design: A cluster, randomised, factorial, controlled trial aimed at including 20 primary care centres (n=2,940 patients) with patients older than 18 years presenting for a first consultation with ALRTI, therefore with presence of infected acute cough of up to 3 weeks' duration as the predominant symptom. Centres, according to socioeconomic and antibiotic consumption, will be randomly assigned according to hierarchical clustering to any of four trial arms: usual care, CRP testing, enhanced communication skills backed up with patient leaflets, or combined interventions. A cost-effectiveness and cost-utility analysis will be performed from the perspective of public health system. A qualitative study aimed at identifying the expectations and concerns in patients with ALRTIs and the satisfaction of clinicians with the different interventions will also be performed. Clinicians assigned to the interventions will participate in a 2-hour training workshop before the inception of the trial and will receive a monthly intervention-tailored training module during the trial. Clinical effectiveness will be measured by the antibiotic use within the first 6 weeks and the quality adjusted life years and secondary outcomes will be duration of illness and severity of cough measured with a symptom diary, healthcare reconsultations, hospital admissions and complications. National health care perspective will be adopted and the temporal horizon of the analysis will be one year. Health care costs will be considered and expressed in € of the current year of the analysis. Univariate and multivariate sensitivity analysis will be carried out.

Discussion: The ISAAC-CAT project aims to improve the management of ALRTIs in primary care through use of two different clinicians' skills to help target antibiotic prescribing only to those most likely to benefit, and thereby reduce the risk of unnecessary exposure to antibiotics leading to adverse effects and/or the development of AMR without having a negative impact on health status, thus benefiting individual patients and society at large. This project will contribute to evaluate the effectiveness and efficiency of different strategies for more appropriate antibiotic prescribing that are currently out of the scope of the actual guidelines.

02

Conditions studied

  • Respiratory Tract Infections
  • Cough

Keywords

  • Antimicrobial Stewardship
  • Cost-Benefit Analysis
  • Anti-Bacterial Agents
  • Primary Health Care
03

In context

Respiratory Tract Infections

1,052 studies on the registry are indexed under Respiratory Tract Infections; 147 are open to participants now.

This study's planned enrollment of 2,940 is above the median of 196 across 715 interventional studies indexed under Respiratory Tract Infections.

Browse Respiratory Tract Infections studies →

Lead sponsor

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina is the lead sponsor of 160 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age equal or older than 18 years
  • first consultation for acute cough (new cough or worsening of a previous cough) as the predominant symptom
  • of up to 3 weeks' duration
  • which the clinician believes to be an infectious acute lower respiratory tract infection

Exclusion criteria

Exclusion Criteria:

  • a working diagnosis of a non-infective disorder, such as heart failure, pulmonary embolus, oesophageal reflux, or allergy
  • use of antibiotics in the previous two weeks
  • immunological deficiencies, and/or
  • inability to provide informed consent or unable to follow the study procedures
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
2,940 participants (estimated)

Study arms

  • Experimental
    C-reactive protein rapid testing

    Continuous (workshop and monthly web-based training) disease-focused intervention with the use of C-reactive protein rapid testing.

    Diagnostic Test: C-reactive protein rapid testing

  • Experimental
    Enhancement of communication skills

    Continuous (on-site and monthly online training) illness-focused intervention with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.

    Procedure: Communication skill enhancement

  • Experimental
    C-reactive protein + communication skills

    Continuous (workshop and monthly web-based training) disease-focused intervention with C-reactive protein rapid testing and on-site and continuous (monthly online training illness-focused intervention) with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.

    Diagnostic Test: C-reactive protein rapid testing · Procedure: Communication skill enhancement

  • No intervention
    Usual care

    Usual care.

Interventions

  • Diagnostic testC-reactive protein rapid testing

    Continuous (workshop and monthly web-based training) disease-focused intervention with the provision of CRP rapid testing in the primary care practices.

    Also known as: CRP

  • ProcedureCommunication skill enhancement

    Continuous (on-site and monthly online training) illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) in the primary care practices.

    Also known as: Leaflet provision

06

What researchers measure

Primary outcomes

  1. Antibiotic use

    Number of antibiotics consumed (as documented in the CRFs and double-checked by the Pharmacy Unit of Institut Català de Salut that can track if the antibiotic has been dispensed at any of the Catalan pharmacies)

    Time frame: Day 42

  2. Health status

    Quality of life score obtained using the EuroQol questionnaire

    Time frame: Difference between baseline visit and day 42

Secondary outcomes

  1. Re-consultations and complications

    Number of re-consultation for new or worsening symptoms, new signs, or hospital admission, assessed by review of medical notes (practice staff, the local study team, or both using a standard form to report these data), and Number of complications regarding the ALRTI

    Time frame: Day 42

  2. Duration of symptoms and duration of severe symptoms

    Number of days until symptoms are rated daily as 0 (no problem) (information is reported by patients in self-completed diaries)

    Time frame: Day 42

  3. Antibiotic prescription at the baseline visit

    Number of antibiotic prescriptions at the baseline visit, differentiating immediate and delayed antibiotic prescribing, and antibiotic dispensing at the pharmacies

    Time frame: Baseline visit

  4. Drugs other than antibiotics

    Number of non-antibiotic prescriptions (reported by patients in self-completed diaries)

    Time frame: Day 42

  5. Tests ordered by clinicians

    Number of tests ordered by clinicians (reported in the CRF)

    Time frame: Day 42

  6. Patient satisfaction with care

    Patient satisfaction score reported in the symptom diary. Measured with a question that has used in previous studies: How satisfied are you with the consultation? Range from 0 (nothing satisfied) to 5 (extremely satisfied).

    Time frame: Day 14

  7. Patient perception of the usefulness of the information received.

    Patient perception score about the usefulness of the information received. Measured with a question that has used in previous studies: Do you consider that the information received from your doctor has been useful? Range from 0 (nothing useful) to 5 (extremely useful).

    Time frame: Day 14

  8. Patient future consulting intention

    Patient future consulting intention score. Measured with a question that has used in previous studies: Do you think you will attend the doctor in future occasions in case you present the same symptoms? Range from 0 (totally unlikely) to 5 (sure).

    Time frame: Day 14

  9. Serious adverse events

    Number of serious adverse events (assessed by review of medical notes (practice staff, the local study team, or both using a standard form to report these data)

    Time frame: Day 42

  10. Absenteeism

    Number of days of sick leave (collected in the CRFs)

    Time frame: Baseline visit

07

Study locations

1 site
  • La Marina Health Center
    Barcelona, Catalonia 08038, Spain
08

References and documents

Publications

  • Medina-Perucha L, Garcia-Sangenis A, Moragas A, Galvez-Hernandez P, Cots JM, Lanau-Roig A, Borras A, Amo I, Monfa R, Llor C, Berenguera A. Autonomy, power dynamics and antibiotic use in primary healthcare: A qualitative study. PLoS One. 2020 Dec 18;15(12):e0244432. doi: 10.1371/journal.pone.0244432. eCollection 2020. PubMed 33338078 ↗
  • Ruiz R, Moragas A, Trapero-Bertran M, Siso A, Berenguera A, Oliva G, Borras-Santos A, Garcia-Sangenis A, Puig-Junoy J, Cots JM, Morros R, Mora T, Lanau-Roig A, Monfa R, Troncoso A, Abellana RM, Galvez P, Medina-Perucha L, Bjerrum L, Amo I, Barragan N, Llor C. Effectiveness and cost-effectiveness of Improving clinicians' diagnostic and communication Skills on Antibiotic prescribing Appropriateness in patients with acute Cough in primary care in CATalonia (the ISAAC-CAT study): study protocol for a cluster randomised controlled trial. Trials. 2019 Dec 17;20(1):740. doi: 10.1186/s13063-019-3727-3. PubMed 31847912 ↗

Individual participant data

Plan to share: Yes — Reposition in SCENTIA

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: First 15 years after publication

Access criteria: On demand

Data sharing details ↗ · scientiasalut.gencat.cat

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03931577
Collaborators
Universitat Internacional de Catalunya, Fundacio d'Atencio Primaria, Universitat Pompeu Fabra
Responsible party
Sponsor
First posted
Apr 30, 2019
Start date
Nov 1, 2019 (estimated)
Primary completion
Feb 28, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Apr 30, 2019

Study contacts

Ana Moragas, MD PhD
Contact
anamaria.moragas@urv.cat
0034600072170 ext. 0034600072170
Ana Garcia-Sangenis, MD
Contact
agarcia@idiapjgol.org
0034934824124 ext. 0034934824124
Rosa Morros, MD PhD
study chair · Clinical pharmacologist

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion